Skip to content
Logo
  • Solutions
    Solutions
    • R&D Teams
    • Regulatory Teams
    • Commercial Teams
    • HEOR Teams
    • Cancer Centers and Oncologists
  • Products
    Products
    • Focus
    • Vantage
    • Vista
    • Clinicogenomics
    • Real-World Analytics
  • Services
    Services
    • Real-World Insights & Support
  • About Us
    About Us
    • Our Mission
    • Careers
  • Resources
    Resources
    • Research
    • Blog
    • News
    • Podcasts
    • Case Studies

    COTA Research Recognized at ASH 2025: Advancing Real-World Evidence in Hematologic Malignancies

    Read More

    COTA Names C.K. Wang, MD as Chief Executive Officer, Reinforcing Its Commitment to Trusted, High-Quality Oncology Data and Services

    Read More
Contact Us

Day: April 10, 2023

What to know about FDA draft guidance on accelerated approval of oncology drugs

Are you up to date with the latest FDA guidance on accelerated approvals for oncology therapeutics? The FDA has just released draft guidance on the use of randomized controlled trials (RCTs) versus single-arm trials for the accelerated approval of oncology therapies. We’ve broken down what you need to know.

Logo
footer-background
Solutions
  • R&D Teams
  • Regulatory Teams
  • Commercial Teams
  • HEOR Teams
  • Oncology Providers
Products & Services
  • Focus
  • Vantage
  • Vista
  • Clinicogenomics
  • Real-World Analytics
  • Real-World Insights & Support
About Us
  • Our Mission
  • Careers
  • Become a Data Partner
Follow Us
  • LinkedIn
  • Real World Talk with COTA
  • Real World Talk with COTA
© 2025 COTA. All rights reserved.
  • Privacy Policy
  • Terms of Service
  • CCPA Privacy Notice